Supplemental Figure 1. Chemical denervation with 6-hydroxydopamine (6-OHDA) reduces expression of tyrosine hydroxylase in hypertensive BPH/2J. Representative images of tyrosine hydroxylase expression in the hearts of BPH/2J control mice **(A)** or 6-OHDA treated mice **(B)**. Tyrosine hydroxylase staining is indicated with arrows. Magnification 200X. **(C)** Quantitation of tyrosine hydroxylase expression in the hearts of BPH/2J mice, n=3-4 mice/group. Representative images of tyrosine hydroxylase expression in kidney from control mice **(D)** or 6-OHDA treated mice **(E)**. Tyrosine hydroxylase staining is indicated with arrows. Magnification 200X. **(F)** Quantitation of tyrosine hydroxylase expression in the kidneys of BPH/2J mice, n=3-4 mice/group. *p<0.05; All data presented as mean ± SEM.



Online Figure 1

Supplemental Figure 2. Chemical denervation with 6-hydroxydopamine (6-OHDA) reduces sodium glucose cotransporter 2 (SGLT2) expression in kidneys of hypertensive BPH/2J mice. Representative immunohistochemistry images of SGLT2 expression in kidneys from BPH/2J control mice **(A)** or 6-OHDA treated mice **(B)**. Examples of SGLT2 staining, which was quantitated in Figure 1E, is indicated with arrows. Magnification 200X.



Online Figure 2

Supplemental Figure 3. Sodium glucose cotransporter 2 (SGLT2) expression is not altered in kidneys of hypertensive BPH/2J mice after Dapagliflozin treatment. (A) Percentage of proximal tubules expressing SGLT2 in kidneys from BPH/2J control mice or Dapagliflozin treated mice, n= 4 mice/group. **(B)** Intensity of staining of proximal tubules in kidneys rated on a scale of 0-3, 0=no staining, 1=low staining, 2=intermediate staining, 3=highest staining, n= 4 mice/group. All data presented as mean ± SEM.



Online Figure 3

Supplemental Figure 4. Sodium glucose cotransporter 2 (SGLT2) inhibition reduces tyrosine hydroxylase expression in the heart of hypertensive BPH/2J mice. Quantitation of tyrosine hydroxylase staining in hearts from BPH/2J control mice or Dapagliflozin treated mice, n= 6-8 mice/group. Data presented as mean ± SEM.



Online Figure 4

Supplemental Figure 5. Interleukin-10 expression is elevated in hearts of hypertensive BPH/2J mice after Dapagliflozin treatment. Interleukin-10 protein levels in hearts from BPH/2J control mice or Dapagliflozin treated mice, n= 7-10 mice/group. Data presented as mean ± SEM.



Online Figure 5

Supplemental Figure 6. Sodium glucose cotransporter 2 (SGLT2) inhibition elevates fecal short chain fatty acids in hypertensive BPH/2J mice. Acetate **(A)** and Butyric acid **(B)** concentrations were measured in the cecal contents of BPH/2J control mice or Dapagliflozin treated mice, n= 6-10 mice/group. All data presented as mean ± SEM.



Online Figure 6